Sign in
Enrolling by invitationNo phase

Vonoprazan Test for PPI Refractory GERD

Key facts

Who runs it
Fu Jen Catholic University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
100 people, planned
Started
24 Dec 2025
Planned end
28 Oct 2026
Type of study
Interventional
Treatments tested
  • Patients received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®)
Record updated
27 February 2026

Who can take part

Age
20 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients aged between 20 and 75 years
  • Outpatients at Fu Jen Catholic University Hospital who had undergone esophagogastroduodenoscopy (EGD) within the past year
  • Presence of persistent GERD symptoms, including acid regurgitation, heartburn, chest pain, globus sensation, or chronic cough. PPI-refractory GERD, defined as persistent symptoms despite receiving at least 8 weeks of standard-dose proton pump inhibitor (PPI) therapy (GerdQ > = 8)
  • Scheduled to undergo high-resolution manometry (HRM) and 24-hour esophageal pH-impedance monitoring
  • Patients with a history of any grade of erosive esophagitis confirmed by gastroscopy

Who cannot take part

  • patients currently taking atazanavir sulfate or rilpivirine hydrochloride,
  • major esophageal motility disorders
  • history of upper gastrointestinal surgery
  • malignant tumors
  • significant acute GI bleeding
  • severe renal impairment (CrCl < 30 mL/min)
  • hypersensitivity to vonoprazan or its excipients
  • liver cirrhosis
  • esophageal strictures
  • esophageal varices
  • gastrointestinal obstruction
  • LA Grade B, C, or D erosive esophagitis,
  • esophageal peptic stricture
  • biopsy-proven Barrett's esophagus
  • long-term dialysis, pregnancy
  • dependent on tube feeding
  • unable to cooperate due to impaired consciousness

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 20 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Among patients suffering from gastroesophageal reflux disease (GERD) symptoms, esophageal pH monitoring and the assessment of symptom-reflux correlation can identify two distinct subgroups characterized by normal acid exposure: functional heartburn and reflux hypersensitivity. Given the absence of abnormal acid exposure in these groups, conventional antacid therapies often yield unsatisfactory clinical outcomes.

Read full original descriptionShow less

Therefore, in cases of PPI-refractory GERD, it is hypothesized that patients with underlying abnormal acid reflux will respond to Vonoprazan, a more potent potassium-competitive acid blocker (P-CAB). Conversely, those whose symptoms are unrelated to acid reflux are expected to show poor response. For future refractory patients without definitive endoscopic evidence of GERD (such as Los Angeles Grade B, C, or D esophagitis, peptic stricture, or histologically confirmed Barrett's esophagus), a Vonoprazan therapeutic trial could potentially bypass the need for invasive high-resolution manometry (HRM) and 24-hour pH-impedance monitoring. Evaluating the efficacy of Vonoprazan may offer diagnostic insights while minimizing patient discomfort and reducing overall healthcare expenditures.

The group in the trial

  • single arm. All patient received VonoprazanOther group

    Patients scheduled for high-resolution manometry (HRM) and 24-hour esophageal pH-impedance monitoring due to GERD symptoms were invited to participate in this study. Following the attainment of informed consent, participants completed a series of GERD-related questionnaires on the day of their examination. Subsequently, they were prescribed a 4-week course of VOCINTI®, a potassium-competitive acid blocker (P-CAB), at a daily oral dose of vonoprazan 20 mg. At the 4-week follow-up visit, the clinical reports for HRM and 24-hour pH-impedance monitoring were reviewed. During this visit, patients completed the GERD-related questionnaires for a second time. Subsequent therapeutic management was then determined based on the comprehensive diagnostic results.

    Treatment: Patients received a 4-week treatment of vonoprazan 20 mg once daily (VOCINTI®)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Vonoprazan Test for Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease
Criteria questions
Built from NCT07437768, who can take part
Record updated
27 February 2026